Novo Nordisk A/S NVO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About NVO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Novo Nordisk A/S is a Danish multinational pharmaceutical company focused primarily on diabetes care, obesity treatment, and rare disease therapeutics. The company operates within the global biopharmaceutical industry and is widely recognized for its leadership in insulin products, GLP-1 receptor agonists, and obesity-management medicines. Its core revenue drivers include diabetes treatments such as Ozempic and Rybelsus, obesity therapies including Wegovy, and biopharmaceutical products targeting hemophilia, growth disorders, and rare endocrine diseases. The company serves healthcare systems, hospitals, pharmacies, and patients across both developed and emerging markets, with significant exposure to the United States and Europe.
Novo Nordisk traces its origins to the 1920s through the founding of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium in Denmark. The two companies merged in 1989 to form Novo Nordisk A/S. Over time, the company evolved from a regional insulin manufacturer into one of the world’s largest diabetes-care businesses through sustained investment in biotechnology, peptide-based therapeutics, and chronic disease management. Its strategic positioning is supported by extensive expertise in biologics manufacturing, a strong intellectual property portfolio, global distribution capabilities, and long-term specialization in metabolic diseases.
Business Operations
Novo Nordisk organizes its operations primarily across the business areas of Diabetes and Obesity Care and Rare Disease. The Diabetes and Obesity Care segment generates the majority of company revenue through insulin products, GLP-1 therapies, oral antidiabetic medicines, and obesity treatments. The Rare Disease segment includes products for hemophilia, growth hormone deficiencies, and rare endocrine disorders. Revenue is generated through pharmaceutical product sales distributed via wholesalers, pharmacies, hospitals, and healthcare providers worldwide.
The company maintains major research, development, and manufacturing capabilities across Europe, North America, Asia, and Latin America. Novo Nordisk controls significant biologics manufacturing infrastructure, including facilities for insulin and peptide production. Strategic assets include advanced drug-delivery technologies and large-scale fermentation capabilities. The company operates alongside subsidiaries such as Novo Nordisk Inc., NNIT (historically associated through ownership interests), and Dicerna Pharmaceuticals, which Novo Nordisk acquired to strengthen its RNA interference research capabilities. Novo Nordisk has also maintained research collaborations with biotechnology firms and academic institutions focused on cardiometabolic diseases and next-generation therapeutics.
Strategic Position & Investments
Novo Nordisk’s strategic direction centers on expanding its leadership in obesity and diabetes care while broadening into adjacent chronic disease categories. The company has significantly increased investment in GLP-1 therapies due to strong global demand for obesity and metabolic treatments. Major growth initiatives include expanding manufacturing capacity, accelerating clinical development programs, and increasing penetration in obesity-care markets. The company has also invested heavily in cardiovascular and kidney disease research linked to metabolic disorders.
Recent acquisitions and investments have supported Novo Nordisk’s long-term pipeline strategy. The acquisition of Dicerna Pharmaceuticals strengthened its RNA interference technology platform, while the acquisition of Inversago Pharma expanded exposure to cannabinoid receptor-based obesity therapies. Novo Nordisk is also involved in emerging therapeutic areas including next-generation obesity medicines, oral peptide technologies, and precision medicine applications. Public filings and investor communications indicate continued emphasis on scaling production infrastructure to address sustained global demand for Wegovy and Ozempic products.
Geographic Footprint
Novo Nordisk is headquartered in Bagsværd, Denmark, and operates in more than 170 countries worldwide. The company maintains major commercial and operational presence across North America, Europe, Asia-Pacific, Latin America, and selected markets in the Middle East and Africa. The United States represents the company’s largest individual market by revenue, supported by broad distribution networks and relationships with healthcare providers and pharmacy benefit managers.
The company’s manufacturing and research footprint spans multiple continents, including production facilities in Denmark, France, Brazil, China, and the United States. Novo Nordisk continues to expand internationally through investments in production capacity and localized operations designed to support growing global demand for diabetes and obesity treatments. Its influence within global healthcare markets is reinforced by participation in public-health initiatives related to chronic disease management and access to insulin therapies in lower-income regions.
Leadership & Governance
Novo Nordisk operates under a governance structure influenced by the Novo Nordisk Foundation, which exercises controlling voting influence through Novo Holdings A/S. The company’s leadership strategy has consistently emphasized long-term scientific investment, chronic disease specialization, and sustainable business growth. Public statements from management and annual reporting emphasize innovation in metabolic disease treatment, scalable biologics manufacturing, and global patient access initiatives.
Key executives include:
- Lars Fruergaard Jørgensen – President and Chief Executive Officer
- Karsten Munk Knudsen – Executive Vice President and Chief Financial Officer
- Martin Holst Lange – Executive Vice President for Development
- Marcus Schindler – Executive Vice President and Chief Scientific Officer
- Camilla Sylvest – Executive Vice President, Commercial Strategy & Corporate Affairs
- Douglas Langa – Executive Vice President, North America Operations
Leadership information, operating structure, and strategic initiatives are consistently disclosed through SEC filings, annual reports, and investor presentations. Financial and operational details are broadly corroborated by major financial publications and market-data providers. Where operational metrics or forward-looking manufacturing projections vary across reporting periods, data may differ depending on the publication date of company disclosures.